WP
ABBV icon

Waycross Partners’s AbbVie ABBV Stock Holding History

Waycross Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3M Buy
167,931
+1,988
+1% +$428K 3.6% 10
2026
Q1 		$36.1M Sell
165,943
-16,533
-9% -$3.67M 3.45% 10
2025
Q4 		$41.7M Buy
182,476
+5,063
+3% +$1.15M 3.41% 10
2025
Q3 		$41.1M Buy
177,413
+8,077
+5% +$1.64M 3.53% 11
2025
Q2 		$31.4M Buy
169,336
+12,050
+8% +$2.24M 2.96% 13
2025
Q1 		$33M Buy
157,286
+22,282
+17% +$4.33M 3.69% 8
2024
Q4 		$24M Buy
135,004
+4,019
+3% +$739K 3.11% 8
2024
Q3 		$25.9M Buy
130,985
+2,718
+2% +$507K 3.58% 7
2024
Q2 		$22M Buy
128,267
+12,086
+10% +$2M 3.38% 8
2024
Q1 		$21.2M Buy
116,181
+6,534
+6% +$1.13M 3.64% 7
2023
Q4 		$17M Sell
109,647
-5,102
-4% -$744K 3.19% 9
2023
Q3 		$17.1M Buy
114,749
+4,653
+4% +$683K 3.78% 6
2023
Q2 		$14.8M Buy
110,096
+18,433
+20% +$2.7M 3.22% 7
2023
Q1 		$14.6M Buy
91,663
+17,067
+23% +$2.61M 4.24% 3
2022
Q4 		$12.1M Buy
74,596
+34,641
+87% +$5.31M 4.37% 3
2022
Q3 		$5.36M Sell
39,955
-285
-0.7% -$40.9K 3.61% 4
2022
Q2 		$6.16M Buy
40,240
+2,348
+6% +$359K 4.09% 3
2022
Q1 		$6.14M Buy
37,892
+3,454
+10% +$502K 3.58% 3
2021
Q4 		$4.66M Buy
34,438
+5,200
+18% +$614K 2.67% 5
2021
Q3 		$3.15M Sell
29,238
-27,362
-48% -$3.13M 1.98% 14
2021
Q2 		$6.38M Buy
56,600
+27,611
+95% +$3.11M 3.39% 6
2021
Q1 		$3.14M Buy
28,989
+12,000
+71% +$1.28M 1.75% 18
2020
Q4 		$1.82M Buy
+16,989
New +$1.63M 1.13% 29

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Waycross Partners's ABBV Position: Q2 2026 in Review

Waycross Partners increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $428K and bringing the position to 167,931 shares worth $42.3M. The position accounts for 3.6% of the portfolio, ranked #10.

Waycross Partners first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Waycross Partners held 167,931 shares of AbbVie worth $42.3M as of Q2 2026.
  • Waycross Partners bought 1,988 AbbVie shares in Q2 2026, an estimated $428K.
  • AbbVie made up 3.6% of Waycross Partners's portfolio in Q2 2026, its #10 holding.
  • Waycross Partners first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Waycross Partners's 13F filing for Q2 2026, filed 11 Aug 2026.